Cost cuts are coming, and “rapidly,” Allergan execs said on Wednesday's Q3 earnings conference call.
Novo Nordisk is counting on multiple new drug launches—including the blockbuster-to-be semaglutide to help overcome market headwinds.
Roche has pulled a cancer drug from the Greek market as it does battle again with authorities over steps taken against drug prices to appease lenders.
Merck KGaA and South Korea’s Samsung BioLogics are deepening a collaboration even as Samsung reported an operating profit for the first time.
Pfizer, struggling to build traction for its Remicade biosimilar in the U.S., has some new data it hopes can make a difference in building sales.
AbbVie took a big step toward putting investors’ minds at ease about aging blockbuster Humira, with better-than-expected third-quarter results.
Despite a cyberattack and a patent loss on a key drug, Merck & Co. beat Street earnings forecast for the third quarter and raised its forecast for the year.
Hepatitis C dominated the discussion on Gilead's third-quarter earnings call—and it wasn’t a positive discussion.
With Opdivo's third straight sales beat of the year in the books, the company has laid investors' 2017 growth worries to rest.
Bayer's third-quarter results are sparking more concern about its Monsanto buy.